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Poxviruses
Poxviruses are a family of large irregularly shaped dsDNA viruses replicating
exclusively in the cytoplasm of the infected cell that include a number of human
and animal pathogens [13]. Most notorious amongst these is the fortunately erad-
icated variola virus (VARV), a highly specific and contagious human virus that
caused smallpox, a disease with mortality rates of up to 30% that has caused
major pandemics recorded as early as 1350 BC. Other poxviruses causing dis-
ease in humans include monkeypoxvirus (MPXV), an emerging zoonotic disease
detected in African countries as well as in the USA with mortality rates of up to
10% [9], molluscum contagiosum virus, which causes benign tumorations mainly
in children, and yaba-like disease virus that causes a mild, self-limiting illness.
The prototypical member of this virus family is vaccinia virus (VACV) which was
used as a live attenuated vaccine for the eradication of smallpox. Lately, recurrent
human infections from circulating VACV-derived viruses adapted to animal hosts
have been detected in India and Brazil, suggesting the potential for adaptation and
re-emergence of these viruses. Additionally, poxviruses are currently under study
for the development of vaccines and use in oncolytic therapies. Therefore, compre-
hension of the mechanisms of pathogenesis and a better understanding of the host
immune modulation strategies used by poxviruses are essential.
Poxviral TNF-Binding Proteins
Concurrently with the first identification and molecular cloning of the human
TNFRs in 1990 [11, 22, 27], Smith and colleagues identified a putatively secreted
viral protein termed T2 in Shope fibroma virus, a poxvirus infecting rabbits, with
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similarity to the TNFR family. Indeed, they proposed that this could act as a soluble
TNF or related cytokine receptor and that such a protein “would no doubt confer a
selective advantage to the pathogen” [27]. Since then, most poxviruses have been
shown to encode at least one predicted active secreted TNF-binding protein, which
can be divided into two groups based on their primary sequences. A class of these
TNF inhibitors termed viral TNFRs (vTNFRs) are homologues to the extracellular
domain of host TNFRs, which are characterized by the presence of a variable num-
ber of copies of the cysteine-rich domain (CRD) that defines the TNFRSF. These
include the mentioned M-T2 protein (and its orthologues present in other viruses
of the Leporipoxvirus genus), four different proteins named cytokine response
modifier B (CrmB), CrmC, CrmD, and CrmE, which are differentially expressed by
members of the poxvirus family, as well as a viral homologue of the TNFRSF mem-
ber CD30. A second class of secreted viral TNF-binding proteins have no amino
acid sequence similarity to known cellular proteins and include the 2L protein of
the yatapoxviruses and their swinepox and deer poxvirus orthologues.
With the exception of the viral CD30 homologue, which was shown to bind
exclusively to cellular TNFSF8 and whose role in pathogenesis is not clearly defined
[3, 15, 21], all other proteins mentioned were found to bind specifically and with
high affinity to TNF and in some cases LT alpha of at least the species infected by
the corresponding virus where they were derived from (see Table 21.1 for a succinct
description of the main properties of these proteins).
The myxoma virus M-T2 protein is most similar to the cellular TNFR2. It
contains four N-terminal CRDs, followed by a C-terminal domain that shows no
similarity to cellular genes. This secreted protein was found to bind to rabbit TNF
with high affinity through its four N-terminal CRDs and inhibit its activity in
cell culture [23]. Additionally, M-T2 was described as a virulence factor during
the development of myxomatosis in infected European rabbits. More recently, the
intracellular pool of M-T2 was shown to have an important role, as it can inhibit
TNF-mediated signaling through PLAD domain-mediated sequestration of cellular
TNFR1, acting effectively as a dominant negative mutant that prevents virus-
induced apoptosis independently of its TNF-binding capability [23–26]. Probably
both activities act in concert in vivo to provide its, however, relatively minor role in
pathogenesis.
The orthopoxviral CrmC and CrmE proteins are composed of only three CRDs
each and, although most similar to the cellular TNFR2, have been found to bind to
TNF but not LT. The possibility that VACV CrmE may act at the cell surface, by
interacting with the cell membrane after secretion, as well as in solution has been
raised [18]. The solution of the crystal structure of the VACV CrmE protein showed
that it adopts a canonical TNFR fold. Although the structure of CrmE complexed
with TNF was not reported, comparison of CrmE with the TNFR structure suggests
that it binds to TNF using the 50s and 90s loops present on CRDs numbers 2 and 3,
respectively. At the moment, this is the only member of the vTNFR family whose
structure has been solved and it may be used as a model to understand the ways in
which these proteins are able to bind to and inhibit their ligands. Thus, it has been
proposed that the 90s loop is involved in fine-tuning ligand specificity and affinity,
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Table 21. 1 Main properties of the poxviral TNF-binding proteins
Protein
Virus (virus
family) Known ligands Role in vivo Reference(s)
2L Tanapox virus
(yatapoxvirus)
TNF
β2microglobulin
Unknown [5, 16, 17, 24, 26, 28,
30]
T2 Shope fibroma
virus, myxoma
virus
(leporipox
virus)
TNF, LTα
TNFR1
Virulence factor
CrmB VARV, MPXV,
CPXV, CMPV,
HSPV
(orthopoxvirus)
TNF, LTα,
chemokines
Anti-
inflammatory,
virulence
factor
[1, 2, 8, 10, 14, 29]
CrmC CPXV, VACV
some strains
only
(orthopoxvirus)
TNF Virulence factor
CrmD ECTV, CPXV
(orthopoxvirus)
TNF, LTα,
chemokines
Unknown [2, 12]
CrmE CPXV, VACV
some strains
only
(orthopoxvirus)
TNF Virulence factor [18, 21]
vCD30 ECTV, CPXV
(orthopoxvirus)
TNFSF8 Modulates Th1
responses in
vivo, not major
virulence
factor during
infection
[3, 15, 21]
whereas the 50s loop may determine the binding affinity of these viral receptors
[9]. Finally, the CrmB and CrmD proteins share a domain structure similar to that
of the M-T2 protein, with four N-terminal CRDs followed by a C-terminal domain
unrelated to TNFRs. Both are secreted proteins and bind with high affinity to TNF
and LT, preventing their biological activity in cell culture assays. Interestingly, these
proteins were found to be able to bind to a reduced set of chemokines (chemotaxis-
inducing cytokines) through their C-terminal domain, which has been named the
SECRET domain (for Smallpox virus-Encoded Chemokine REcepTor) and inhibit
their biological activity in cell culture [2]. The lack of amino acid sequence similar-
ity of the SECRET domain with host chemokine receptors and other virus-encoded
chemokine-binding proteins suggests that this domain represents a new protein
structure able to bind chemokines with high affinity. The TNF and chemokine
ligands were shown to be bound simultaneously through structurally independent
domains of the VARV CrmB and ECTV CrmD proteins, which were proposed to act
as immunomodulatory proteins with dual activities in vivo. Whether this property
may be shared by the M-T2 protein remains to be addressed.
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vTNFRs in Pathogenesis
Somewhat surprisingly given the importance of orthopoxviral infections in humans,
the evidence on the contribution of orthopoxviral vTNFRs to virulence in vivo is
scarce so far.
The CPXV CrmB protein was proposed to have anti-inflammatory activity in
vivo using a chicken embryo chorioallantoic membrane infection model and the
CrmB deletion mutant CPXV showed an approximately 50-fold reduced LD50 in
intracranially infected mice [14]. However, the CPXV strain used still contained
other active vTNFRs, impairing a clear attribution of TNF or chemokine inhibitory
activities to the observed phenomena. Additionally, the model of intracranial infec-
tion used can hardly mimic the natural route of infection. More recently, expression
of CPXV CrmB, VACV CrmC or CrmE proteins from a recombinant attenuated
VACV was shown to increase the virulence using an intranasal mouse model of
infection, but not an intradermal infection model. Deletion of the VACV CrmE, but
not CrmC, did similarly attenuate viral infection in mice using the intranasal model
[18]. This evidence is limited to models that required high virus doses to cause
disease and the effects observed are relatively minor. Lastly, no description of the
possible role of the CrmD protein in vivo has been published yet. Therefore, we
believe that better in vivo models may be necessary for the study of the contribution
of vTNFRs to viral pathogenesis and immune regulation.
Ectromelia Virus
Ectromelia virus (ECTV) is an orthopoxvirus that has host specificity for the mouse
and is genetically very similar to VACV, VARV, and MPXV [7]. Susceptible strains
of mice infected with ECTV develop mousepox that, like smallpox, is a severe dis-
ease with high mortality and infectivity rates, and constitutes an excellent model to
study smallpox. The fact that infection with ECTV in susceptible strains of mice
rapidly becomes systemic when inoculated via the subcutaneous or intranasal route
has been exploited not only as a tool to investigate the pathogenesis and immunology
of poxvirus infections, but also as a model of generalized virus infections, genetic
resistance to disease, and viral immunology [7].
Previous data suggested an important role for TNF-induced signaling in mouse-
pox pathogenesis, as transgenic-resistant mice lacking functional TNFR1 and
TNFR2 became susceptible to ECTV, with highly increased viral titers in the main
target organs, liver and spleen, of the infected mice [20]. Moreover, treatment of sus-
ceptible BALB/c mice with murine TNF was able to hinder ECTV replication and
mortality to some extent [4]. Importantly, ECTV encodes only one active vTNFR,
the CrmD protein, which is expressed as a secreted protein at late times postinfec-
tion. VARV, the causative agent of human smallpox, does similarly encode only one
secreted vTNFR predicted to be active, the CrmB protein. As mentioned before,
both proteins have been characterized and shown to have similar binding properties
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in vitro. For these reasons, ECTV constitutes an excellent model for the study of the
role of vTNFRs in the pathogenesis of orthopoxviral infections.
To address this issue, we have constructed a recombinant ECTV lacking the gene
encoding CrmD and studied its virulence in vivo. Experiments performed in cell
culture confirmed that this deletion mutant did not express any detectable soluble
TNF-binding activity and that deletion of CrmD did not alter the replication capac-
ity of the virus. When infected into susceptible BALB/c mice, however, the CrmD
deletion mutant was found to be severely attenuated, with an LD50 reduced by at
least six orders of magnitude. Moreover, absence of CrmD was accompanied by a
strong and quick inflammatory response at the initial infection site and reduced viral
spread to the main target organs, spleen and liver. This identifies CrmD as one of
the main determinants of mousepox virulence in vivo, suggesting that the related
CrmB protein found in VARV might be of similar importance during the develop-
ment of human smallpox. Interestingly, the TNF-regulated response in macaques
experimentally infected with VARV was impaired as compared to infections with
other viruses [19], suggesting an active viral TNF-blocking mechanism which may
be mediated by the CrmB protein, amongst others.
Given that CrmD is able to block both TNF and chemokines simultaneously, we
propose a working model (see Fig. 21.1) in which blockade of TNF hinders the
establishment of a proinflammatory state locally, while chemokine blockade further
impairs the ensuing recruitment of leukocytes to the initial infection site. This may
allow enhanced replication and spread of the virus through the infected host by
preventing the establishment of an adequate antiviral immune response in vivo.
viral infection
leukocyte
vascular endothelium
TNF
proinflammatory state
CK
CrmD
BA
Fig. 21.1 Proposed working model for the CrmD protein. (a) In response to viral infection,
TNF and other proinflammatory cytokines are produced. This proinflammatory state promotes
the expression of chemokines (CK) that will recruit leukocytes to the site of infection to eliminate
or control the incoming virus. (b) In the presence of the secreted TNF and CK inhibitory protein
CrmD expressed by ECTV infected cells, this reaction is blocked in two steps by first impairing
the establishment of a proinflammatory state and later directly preventing leukocyte migration
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To further understand the molecular mechanisms of CrmD activity during infec-
tion, we are currently studying in greater detail the structural determinants of CrmD
interactions with its TNF/LT and chemokine ligands. Our aim is to generate recom-
binant ECTV expressing mutant versions of the protein binding to only one of its
known ligands at a time. This will allow us to determine the individual contribution
of these cytokines in the establishment of the antiviral response. This approach will
also help us to understand the structural basis of the CrmD–ligand binding that could
be used as a model to study molecularly the TNFSF–TNFRSF interaction, since sur-
prisingly, despite the importance of these cytokines in the immune response, there
are few data about the structural features of the ligand–receptor complexes.
Conclusions
In this study, we demonstrate that CrmD is an essential virulence factor, as dele-
tion of CrmD from ECTV resulted in an avirulent virus that induced an acute
early inflammatory response at the initial site of infection but did not establish a
fatal disease. This is one of the most dramatic attenuation phenotypes described
in poxviruses after inactivation of a viral immune modulatory activity and demon-
strates a critical role of TNF and a reduced set of chemokines in antiviral defence.
Moreover, this unique experimental model of virus infection will allow us to
dissect in vivo the relative contribution of TNF and chemokine activities to the
establishment of an adequate immune response.
Anti-TNF therapy, based on either monoclonal antibodies or soluble TNFRs,
is available in the clinic as an efficient way of blocking adverse inflammatory
responses. A better knowledge of the strategies used by viruses to modulate TNF
activity during infection may uncover new anti-TNF strategies that could be applied
to the clinic. The use of soluble versions of TNFRs by viruses confirms an adequate
strategy used in the clinic. A better understanding of the function of the differ-
ent vTNFRs in vivo may help us to improve even further the potency of soluble
TNFRs in blocking adverse inflammatory responses in a number of human disease
conditions.
The investigations described here on viral strategies to modulate the activity of
TNF illustrate how a better understanding of the interaction of viruses with the host
immune system may provide information relevant to viral pathogenesis and suggest
new strategies of immune modulation for the treatment of human disease.
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